Although there is overall consensus among the families in favour of routine neonatal screening for DMD, five of seven subsequent pregnancies reported in six women were not monitored by prenatal diagnosis and have resulted in the birth of two affected boys. In a comparable time interval, prenatal diagnosis was acceptable to carrier females whose affected male relatives were traditionally diagnosed at four or five years. We conclude that, although molecular genetic analysis now allows for precise diagnosis of DMD, highly accurate carrier testing and prenatal diagnosis, very early DMD carrier identification, and genetic counselling after the identification of DMD males in a population based neonatal screening programme may not be an effective way of decreasing the number of repeat cases of DMD within families or the overall population frequency of DMD.
Abstract
In a pilot neonatal screening programme for Duchenne muscular dystrophy (DMD) conducted in the Canadian province of Manitoba, a cohort of eight affected males was identified between 1 January 1986 and 31 December 1989. Demographic information, knowledge of DMD, reproductive outcome, and attitudes to prenatal diagnosis and neonatal screening for DMD were obtained through questionnaires distributed in May 1992 to the eight sets of parents of index cases, two high probability carrier aunts, and one high probability carrier sister. Personal interviews were subsequently conducted in the summer of 1992. Although there is overall consensus among the families in favour of routine neonatal screening for DMD, five of seven subsequent pregnancies reported in six women were not monitored by prenatal diagnosis and have resulted in the birth of two affected boys. In a comparable time interval, prenatal diagnosis was acceptable to carrier females whose affected male relatives were traditionally diagnosed at four or five years. We conclude that, although molecular genetic analysis now allows for precise diagnosis of DMD, highly accurate carrier testing and prenatal diagnosis, very early DMD carrier identification, and genetic counselling after the identification of DMD males in a population based neonatal screening programme may not be an effective way of decreasing the number of repeat cases of DMD within families or the overall population frequency of DMD. (J Med Genet 1993; 30:670-4) Neonatal screening for Duchenne muscular dystrophy (DMD) has been in place in the province of Manitoba, Canada as a pilot programme since 1 with grandparents in another country. The fifth unmonitored pregnancy is in a woman with a low risk of being a DMD carrier based on molecular analysis of a gene deletion.5 She was offered CVS and understood the possibility of undetected gonadal mosaicism but declined prenatal testing primarily because, as seen in table 3, termination of an affected pregnancy would not be considered. A male child has been born and is considered not to be affected with DMD on the basis of a normal CK level and the absence of any detectable molecular alteration in the dystrophin gene.
Overall, the amount of social chaos in the lives of the four high risk women who did not request prenatal diagnosis seems disproportionately high for our small number of index families, but does seem to correspond to their lower Hollingshead social class reflecting education and occupation. The socially disrupted lives of these women appear to be one important factor in their reproductive decision making.
Of importance to note are the relatively mild clinical signs in the affected males at the time of the mother's subsequent pregnancy. At the time of subsequent pregnancy, three affected males had a positive Gower sign and two children had shown delayed motor milestones but were Gower sign negative. Two, however, were globally developmentally delayed. The paucity of striking clinical symptoms in the majority of very young affected males ascertained by newborn screening as opposed to the time of traditional diagnosis at 4 or 5 years of age may also contribute towards denial of the diagnosis and affect the decision to reproduce further or to continue with a pregnancy once conceived without prenatal diagnosis. This reluctance to terminate an affected pregnancy is seen in other disorders where there is no associated mental retardation and lifespans extend beyond early childhood.7 The complex psychology behind the decision to request termination of an affected pregnancy while still caring for and loving an affected but apparently healthy child showing mild symptoms, if any, cannot be ignored. The uncertainty as to whether to seek prenatal diagnosis and request termination of an affected pregnancy seems to be less in single gene disorders where gross developmental delay or handicap is apparent from infancy and therefore evident to the parents at the time of subsequent pregnancy.89 As well, in our experience, prenatal diagnosis and termination of pregnancy requests are acceptable to high risk DMD carriers identified after traditional clinical diagnosis of DMD in their families in that four requests for early prenatal diagnosis in this same time period have been made by such mothers. However, as appropriate comparative data are not available, we are uncertain at present if acceptance of prenatal diagnosis in our population is greater among mothers and female relatives of traditionally diagnosed DMD patients.
With the small number of study families at present it is difficult or impossible to assess the impact of genetic counselling on reproductive choice outcome. This is especially true since in four out of 11 respondents a decision towards limiting family size by permanent sterilisation of one member of the couple had already been made before counselling. All of these decisions seemed largely based on both maternal age and number of previous children. After counselling, a further two out of the 11 women underwent permanent sterilisation. In both cases sterilisation followed subsequent pregnancies. However, in these two instances we feel genetic counselling may have had substantial impact leading towards sterilisation. Only as our sample size grows to include younger women at the beginning of their reproductive years may the impact of genetic counselling be maximally apparent.
Finally, as seen in table 3, all but one of the parties involved felt that the Newborn Screening Programme was helpful and should be introduced as part of routine neonatal screening in this province. The comments supporting these viewpoints were generally that early diagnosis had helped the family prepare for and cope with the physical changes now occurring in affected boys and allowed them to be linked early on with counselling, rehabilitation services, and parent support groups. Three respondents mentioned that early diagnosis may have an impact on further reproductive choice but two of these three respondents were permanently sterilised before genetic counselling. Thus, this statement did not apply directly to themselves. In spite of an overall positive response to routine newborn screening, actual personal satisfaction with the programme involving all the different members of the diagnostic and follow up team were more varied, ranging from enthusiastic endorsement to disappointment. In many cases this reflects denial or difficulty in accepting and coping with the diagnosis of DMD in the preclinical years. In part, the parents may have felt some uncertainty as this is a pilot programme, itself in its infancy.
In summary, six of 11 women who responded to our questionnaire and from whom medical/personal information is available have had pregnancies after the diagnosis of a male affected with DMD in their family. Only two of these seven pregnancies were monitored by prenatal diagnosis. Two affected males were born and subsequently diagnosed as DMD. The only published data on reproductive outcome in other pilot neonatal screening programmes currently under way in North America and Europe is from the group in Lyons, France. The latter investigators with long standing experience in neonatal screening for DMD have not reported an experience similar to ours.'0 Although the very small numbers involved in our study may not accurately reflect the potential impact of genetic counselling on reproductive choice, the tacitly held assumption that early carrier diagnosis will necessarily decrease the number of subsequently affected children, at least in our population, seems premature as it oversimplifies the complex decision of reproductive choice. To this end, newly identified families will con-tinue to be counselled and followed for data collection.
The aim of newborn screening is to reduce the burden of DMD in families. By early identification of affected males leading to very early identification and genetic counselling of carrier females, the birth of repeated affected boys within families may be prevented. Although this aim has yet to be realised, based on the early results of reproductive outcome, the additional positive benefits of neonatal screening in terms of family adjustment, informed reproductive choice, and in the future early therapy for affected children may make neonatal screening for DMD a beneficial endeavour from many different perspectives. 
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